What term is used to describe the specimen where the drug is at its highest serum concentration?

1. Levy G, Ebling WF, Forrest A. Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther. 1994;56:1–8. [PubMed] [Google Scholar]

2. Campbell M. Community-based therapeutic drug monitoring. Clin Pharmacokinet. 1995;28:271–274. [PubMed] [Google Scholar]

3. Aronson JK, Hardman M. Measuring plasma drug concentrations. Br Med J. 1992;305:1078–1080. [PMC free article] [PubMed] [Google Scholar]

4. Birkett DJ. Therapeutic drug monitoring. Australian Prescriber. 1997;20:9–11. [Google Scholar]

5. Spector R, Park GD, Johnson G, et al. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988;43:345–353. [PubMed] [Google Scholar]

6. Bussey HI, Hoffman EW. A prospective evaluation of therapeutic drug monitoring. Ther Drug Monit. 1983;5:245–248. [PubMed] [Google Scholar]

7. Tonkin AL, Bochner F. Therapeutic drug monitoring and patient outcome. Clin Pharmacokinet. 1994;27:169–174. [PubMed] [Google Scholar]

8. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet. 1995;29:29–35. [PubMed] [Google Scholar]

9. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clin Pharmacokinet. 1995;29:442–450. [PubMed] [Google Scholar]

10. Eadie MJ. Indications for plasma drug monitoring in patients with epilepsy. Pharmacoeconomics. 1997;11:343–349. [PubMed] [Google Scholar]

11. Tett S, Ray J, Morris R. Best Practice in Therapeutic Drug Monitoring. 1995. Published.

12. Carroll DJ, Austin GE, Stajich GV, et al. Effect of education on the appropriateness of serum drug concentration determination. Ther Drug Monit. 1992;14:81–84. [PubMed] [Google Scholar]

13. Quattrochi F, Karnes HT, Robinson JD, et al. Effect of serum separator blood collection tubes on drug concentrations. Ther Drug Monit. 1983;5:359–362. [PubMed] [Google Scholar]

14. Pichini S, Alteri I, Zuccaro P, et al. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 1996;30:211–228. [PubMed] [Google Scholar]

15. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet. 1996;30:445–462. [PubMed] [Google Scholar]

16. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication. Ther Drug Monit. 1997;19:1–10. [PubMed] [Google Scholar]

17. Morris R. Cyclosporin A monitoring in Australia: Consensus recommendations. Ther Drug Monit. 1994;16:570–576. [PubMed] [Google Scholar]

18. El Desoky E, Meinshausen J, Bühl K, et al. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs pharmacokinetic studies. Ther Drug Monit. 1993;15:281–288. [PubMed] [Google Scholar]

19. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992;22:447–467. [PubMed] [Google Scholar]

20. Ried LD, McKenna DA, Horn JR. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. Am J Hosp Pharm. 1989;46:945–951. [PubMed] [Google Scholar]

21. Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit. 1990;12:72–78. [PubMed] [Google Scholar]

22. Mattson RH Antiepileptic drug monitoring. a reappraisal. Epilepsia. 1995;36(Suppl 5):S22–S29. [PubMed] [Google Scholar]

23. Freeman DJ, Oyewumi LK. Will therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32:93–100. [PubMed] [Google Scholar]

Page 2

1. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring: a systemic review. Ther Drug Monit. 2005;27:10–17. [PubMed] [Google Scholar]

2. Birkett DJ. Pharmacokinetics made easy: therapeutic drug monitoring. Aust Prescr. 1997;20:9–11. [Google Scholar]

3. Tange SM, Grey VL, Senecal PE. Therapeutic drug monitoring in pediatrics: a need for improvement. J Clin Pharmacol. 1994;34:200–214. [PubMed] [Google Scholar]

4. Reed MD, Blumer JL. Therapeutic drug monitoring in the pediatric intensive care unit. Pediatr Clin North Am. 1994;41:1227–1243. [PubMed] [Google Scholar]

5. Kearns GL, Moss MM, Clayton BD, Hewett DD. Pharmacokinetics and efficacy of digoxin specific Fab fragments in a child following massive digoxin overdose. J Clin Pharmacol. 1989;29:901–908. [PubMed] [Google Scholar]

6. Ohning BL. Neonatal pharmacodynamics-basic principles: I. drug delivery. Neonatal Netw. 1995;14:7–12. [PubMed] [Google Scholar]

7. Ohning BL. Neonatal pharmacodynamics-basic principles: II. drug action and elimination. Neonatal Netw. 1995;14:15–19. [PubMed] [Google Scholar]

8. Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels: a report from the Boston Collaborative Drug Surveillance program. Ann Intern Med. 1974;80:516–519. [PubMed] [Google Scholar]

9. Atkinson AJ, Jr, Nordstorm K. The challenge of in-hospital medication use: an opportunity for clinical pharmacology. Clin Pharmacol Ther. 1996;60:363–367. [PubMed] [Google Scholar]

10. Shenfield GM. Therapeutic drug monitoring beyond 2000. Br J Clin Pharmacol. 2001;52(Suppl 1):3S–4S. [PMC free article] [PubMed] [Google Scholar]

11. Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34:265–279. [PubMed] [Google Scholar]

12. Carrico JM. Human Genome Project and pharmacogenomics: implication for pharmacy. J Am Pharm Assoc. 2000;40:115–116. [PubMed] [Google Scholar]

13. Collins FS. Shattuck lecture: medical and societal consequences of the Human Genome Project. N Engl J Med. 1999;341:28–37. [PubMed] [Google Scholar]

14. Knapp KK. The Human Genome Project. APhA 2000-American Pharmaceutical Association Annual Meeting. [Cited 2000 Jun 2]. Available from: http://www.medscape.com/medscape/CNO/2000/APHA/APHA-04.htm.

15. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304–1351. [f1] [PubMed] [Google Scholar]

16. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(Suppl 1):5S–10S. [PMC free article] [PubMed] [Google Scholar]

17. Dipiro JT, Spruill WJ, Blouin RA, et al. Lesson 1: introduction to pharmacokinetics and pharmacodynamics. In: Dipiro JT, editor. Concepts in Clinical Pharmacokinetics. 3rd ed. Bethesda: ASPS; 2002. pp. 1–11. [Google Scholar]

18. Bochner F, Tonkin A. The clinician and therapeutic drug monitoring in the 1990s. Med J Aust. 1993;158:422–426. [PubMed] [Google Scholar]

19. Reynolds DJ, Aronson JK. ABC of monitoring drug therapy: making the most of plasma drug concentration measurements. BMJ. 1993;306:48–51. [PMC free article] [PubMed] [Google Scholar]

20. Aronson JK, Hardman M. ABC of monitoring drug therapy: measuring plasma drug concentrations. BMJ. 1992;305:1078–1080. [PMC free article] [PubMed] [Google Scholar]

21. Cristodorescu R, Deutsch G, Dragan S. Clinical utility of plasma digoxin measurements. Med Interne. 1989;27:25–32. [PubMed] [Google Scholar]

22. DeVore KJ, Hobbs RA. Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration. Pharmacotherapy. 2007;27:472–475. [PubMed] [Google Scholar]

23. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56:248–252. [PubMed] [Google Scholar]

24. Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokinet. 1987;13:131–140. [PubMed] [Google Scholar]

25. Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988;43:345–353. [PubMed] [Google Scholar]

26. McInnes GT. The value of therapeutic drug monitoring to the practising physician: an hypothesis in need of testing. Br J Clin Pharmacol. 1989;27:281–284. [PMC free article] [PubMed] [Google Scholar]

27. Sjoqvist F. Interindividual differences in drug responses: an overview. In: Rowald M, Sheiner LB, Steiner JL, editors. Variability in Drug Therapy. New York: Raven Press; 1985. pp. 1–10. [Google Scholar]

28. Bowers LD. Analytical goals in therapeutic drug monitoring. Clin Chem. 1998;44:375–380. [PubMed] [Google Scholar]

29. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Fed Regist. 1996;61:9315–9320. [Google Scholar]

30. Winter ME. Part 1: interpretation of plasma drug concentration. In: Winter ME, editor. Basic Clinical Pharmacokinetics. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 73–96. [Google Scholar]

31. Glazko AJ. Phenytoin, chemistry and methods of determination. In: Levy RH, editor. Antiepileptic Drugs. 3rd ed. New York: Raven press; 1989. pp. 159–176. [Google Scholar]

32. Steijns LS, Bouw J, van der Weide J. Evaluation of fluorescence polarization assays for measuring valproic acid, phenytoin, carbamazepine and phenobarbital in serum. Ther Drug Monit. 2002;24:432–435. [PubMed] [Google Scholar]

33. Patel JA, Clayton LT, LeBel CP, McClatchey KD. Abnormal theophylline levels in plasma by fluorescence polarization immunoassay in patients with renal disease. Ther Drug Monit. 1984;6:458–460. [PubMed] [Google Scholar]

34. Hicks JM, Brett EM. Fasely increased digoxin concentration in samples from neonates and infants. Ther Drug Monit. 1984;6:461–464. [PubMed] [Google Scholar]

35. Frank EL, Schwarz EL, Juenke J, et al. Performance characteristics of four immunoassays for antiepileptic drugs on the IMMULITE 2000 automated analyzer. Am J Clin Pathol. 2002;118:124–131. [PubMed] [Google Scholar]

36. Wu SL, Li W, Wells A, dasgupta A. Digoxin-like and digitoxin-like immunoreactive substances in elderly people: impact on therapeutic drug monitoring of digoxin and digitoxin concentrations. Am J Clin Pathol. 2001;115:600–604. [PubMed] [Google Scholar]

37. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem. 2002;48:507–516. [PubMed] [Google Scholar]

38. Somerville AL, Wright DH, Rotschafer JC. Implication of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy. 1999;19:702–707. [PubMed] [Google Scholar]

39. Sym D, Smith C, Meenan G, Lehrer M. Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure? Ther Drug Monit. 2001;23:441–444. [PubMed] [Google Scholar]

40. Larkin JG, Herrick AL, McGuire GM, Percy-Robb IW, Brodie MJ. Antiepileptic drug monitoring at the epilepsy clinic: a prospective evaluation. Epilepsia. 1991;32:89–95. [PubMed] [Google Scholar]

41. Burton ME, Shaw LM, Schentag JJ, Evans WE. Applied Pharmacokinetics & Pharmacodynamics; Principles of Therapeutic Drug Monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. [Google Scholar]

42. Winter ME. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 73–74. [Google Scholar]

43. Bootman JL, Harrison DL. Pharmacoeconomics and therapeutic drug monitoring. Pharm World Sci. 1997;19:178–181. [PubMed] [Google Scholar]

44. Schumacher GE, Barr JT. Economic and outcome issues for therapeutic drug monitoring in medicine. Ther Drug Monit. 1998;20:539–542. [PubMed] [Google Scholar]

45. Schumascher GE, Barr JT. Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics. Clin Chem. 1998;44:370–374. [PubMed] [Google Scholar]

46. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q. 1966;44(Suppl):166–206. [PubMed] [Google Scholar]

47. Barr JT, Schumacher GE. Outcomes assessment of therapeutic drug monitoring. In: Schumacher GE, editor. Therapeutic Drug Monitoring. East Norwalk: Appleton & Lange; 1995. pp. 191–236. [Google Scholar]

48. Rane CT, Dalvi SS, Goptay NJ, Shah PU, Kshirsagar NA. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol. 2001;52:193–195. [PMC free article] [PubMed] [Google Scholar]

49. Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit. 1990;12:72–78. [PubMed] [Google Scholar]

50. Bootman JL, Wertheimer AI, Zaske D, Rowland C. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost-benefit analysis. J Pharm Sci. 1979;68:267–272. [PubMed] [Google Scholar]

51. Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit. 1990;12:419–426. [PubMed] [Google Scholar]

52. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21:63–73. [PubMed] [Google Scholar]

53. Streetman DS, Nafziger AN, Destache CJ, Bertino AS., Jr Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21:443–451. [PubMed] [Google Scholar]

54. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23:643–650. [PubMed] [Google Scholar]

55. Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998;44:381–387. [PubMed] [Google Scholar]

56. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit. 2002;24:59–67. [PubMed] [Google Scholar]

57. Thomson A. Why do therapeutic drug monitoring. Pharm J. 2004;273:153–155. [Google Scholar]

58. Borowitz SM. A monthly refiew for health care professionals of the chieldren's medical center: therapeutic drug monitoring in pediatric patients. Pediatr Pharmacother. 1995;1:1–10. [Google Scholar]

Page 2